Asian ginseng Panax ginseng C.A.Mey.
Also called: Korean ginseng, Chinese ginseng, red ginseng, white ginseng, Panax ginseng
Asian ginseng is native to Korea, northeastern China and far-eastern Siberia. The root is the part most used. 'Red' and 'white' ginseng are the same plant prepared in two different ways.
- Category
- Botanical
- Part used
- Root
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-28
Class 1 Well studied in people. A 2022 meta-analysis (J Ginseng Res) pooled 23 RCTs (27 datasets) of oral Panax ginseng or Korean red ginseng on blood glucose, blood pressure and lipids; studies giving ginseng as part of a complex intervention were excluded. [4]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BHormones and reproduction1 topic
CBrain, mood and sleep2 topics
CHeart and blood vessels1 topic
XMuscles and exercise1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| General fatigue | C | A 2023 review of 19 studies (2,413 participants) suggested a small benefit for general fatigue from ginseng alone; not all research agrees. [1] |
| Cardiometabolic measures in prediabetes and diabetes | C | A 2022 review of 20 studies (1,295 participants) reported improved fasting glucose and other factors, but NCCIH calls blood-sugar research overall inconclusive and conflicting. [1] |
| Erectile dysfunction | B | NCCIH states some research shows oral Asian ginseng seems to improve sexual function in people with erectile dysfunction. [1] |
| Cognitive function | C | A small amount of research suggests improvement in middle-aged but not young adults; memory benefit appeared to depend on adding ginkgo. [1] |
| Athletic performance | X | NCCIH states the majority of research shows Asian ginseng does not improve athletic performance. [1] |
Main constituents: Ginsenosides (panaxosides), thought to be the most important constituents [1]; 30 different triterpene saponins (ginsenosides and panaxosides); content varies widely between products, and some contain none [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Recommended daily amounts vary widely (100 to >1,000 mg daily) depending on preparation and intended use. [2]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score EABCDEA: well known causeE: unlikely cause
LiverTox likelihood score E: by itself, unlikely cause of clinically apparent liver injury (chapter last updated March 14, 2018).
Details and sources - Pregnancy and breastfeedingEU monograph: safety during pregnancy and lactation has not been established …
3 statements in the profile.
Details and sources - Interactions with medicines5 listed
Warfarin; Imatinib and raltegravir; Drugs metabolized by CYP3A4; Antidepressants, blood thinners and digoxin; Medicines in general
Details and sources - Cancer evaluations (IARC, NTP)1 found
Each names the exact material tested, which may differ from a supplement.
Details and sources - FDA new dietary ingredient notifications8 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographs2 statements
EU herbal monograph, traditional use (EMA/HMPC/27744/2023, adopted 29 May 2024), adults and elderly, examples: powdered white ginseng root, single …
Details and sources
- Short-term oral use (up to 6 months) in recommended amounts appears safe for most people; long-term safety has been questioned. [1]
- Insomnia is the most common side effect; severe rash, liver damage and severe allergic reactions are uncommon reports. May worsen autoimmune disorders and interfere with blood clotting. [1]
- Might lower blood sugar; people with diabetes should consult a clinician first. [1]
- May be unsafe orally in pregnancy (one constituent caused birth defects in animals); some experts advise against use in infants, children, and during pregnancy or breastfeeding. [1]
- LiverTox likelihood score E (by itself, unlikely cause of clinically apparent liver injury). [2]
Interactions
| With | What happens |
|---|---|
| Warfarin | In one patient, INR fell from 3.0–4.0 to 1.5 after starting ginseng and returned to baseline when it was stopped. [2] |
| Imatinib and raltegravir | Liver injury developed after ginseng was added in patients who had tolerated these drugs; they tolerated the drugs again once ginseng was stopped. [2] |
| Drugs metabolized by CYP3A4 | Some ginseng preparations may inhibit CYP3A4 enough to affect the metabolism of other drugs. [2] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Ginsenoside content varies widely between commercial products, and some have none. [2]
Regulatory status
- US: herbal products for oral use are often marketed as dietary supplements, which, unlike drugs, are not approved by the FDA before sale; manufacturers are responsible for safety and labeling. [1]
- EU: an EU herbal monograph covers traditional use (based on long-standing use, not clinical studies) of ginseng root preparations for symptoms of asthenia such as fatigue and weakness. [3]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 8 entries naming Panax ginseng, mostly as one ingredient of a combination or as a berry extract (earliest NDI 271 submitted 2004-01-07; most recent NDI 1193 submitted 2020-12-31). A further 11 entries name 'ginseng', 'Radix ginseng' or red, black or Korean red ginseng without a species name (most recent NDI 1362 submitted 2024-09-26), and one more (NDI 165, submitted 2002-07-10) is an EPA/DHA fish-oil ingredient with 'Ginseng Fish Oil' in its name; entries naming Panax notoginseng or Panax quinquefolius are not counted. Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P7]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- LiverTox likelihood score E: by itself, unlikely cause of clinically apparent liver injury (chapter last updated March 14, 2018). [P2]
Interactions with medicines
- Warfarin: LiverTox: in one patient, INR fell from 3.0-4.0 to 1.5 after starting ginseng and returned to baseline when it was stopped. [P2]
- Imatinib and raltegravir: LiverTox: liver injury developed after ginseng was added in patients who had tolerated these drugs; they tolerated the drugs again once ginseng was stopped. [P2]
- Drugs metabolized by CYP3A4: LiverTox: in vitro studies found that different ginsenosides have different effects on cytochrome P450 activity and some may inhibit CYP3A4 enough to affect the metabolism of other drugs; different ginseng preparations may therefore show varying degrees of herb-drug interaction. [P2]
- Antidepressants, blood thinners and digoxin: Health Canada monograph label statement: ask a health care practitioner before use if taking these medicines. [P4]
- Medicines in general: EU monograph (2024): no interactions reported. [P3]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component — US cGMP rule for dietary supplements: at least one appropriate test or examination must verify the identity of any component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)); exemption only through a petition FDA grants (111.75(a)(1)(ii)). [P8]
- Microscopy of root or powder (secretory ducts, starch grains, xylem vessels) combined with HPLC-UV ginsenoside profile — Distinguished Panax species from Codonopsis pilosula and Platycodon grandiflorus; P. ginseng and P. quinquefolius remained anatomically very similar. [P11]
- Ginsenoside content assay — Ginsenoside content varies widely between commercial products, and some contain none. [P2]
Supply and conservation
- IUCN Red List: Critically Endangered (CR), via GBIF species API, retrieved 2026-10-29. [P9]
- CITES Appendix II, only the population of the Russian Federation (no other population is included in the Appendices), current listing effective 12 June 2013; annotation #3 covers whole and sliced roots and parts of roots, excluding manufactured parts or derivatives such as powders, pills, extracts, tonics, teas and confectionery. [P10]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU herbal monograph, traditional use (EMA/HMPC/27744/2023, adopted 29 May 2024), adults and elderly, examples: powdered white ginseng root, single dose 250-1200 mg, daily dose 600-2000 mg; dry extract (DER 3-7:1, ethanol 40% V/V, 4% ginsenosides), 40-200 mg daily. Duration of use up to 3 months; use under 18 is not recommended. [P3]
- Health Canada, Panax ginseng monograph (June 27, 2025), adults 18 and older: 200-600 mg per day of dry extract standardized to 4-7% total ginsenosides (not exceeding 9 g dried root per day), or 0.5-9 g dried root/rootlets per day; Traditional Chinese Medicine: 3-10 g dried root per day as decoction, or 0.5-4 g as unextracted powder. [P4]
Pregnancy and breastfeeding
- EU monograph: safety during pregnancy and lactation has not been established; in the absence of sufficient data, use during pregnancy and lactation is not recommended. [P3]
- Health Canada monograph label statement: ask a health care practitioner before use if pregnant or breastfeeding. [P4]
- NCCIH: may be unsafe orally in pregnancy (one constituent caused birth defects in animals); some experts advise against use in infants, children, and during pregnancy or breastfeeding. [P1]
Sources for this profile
- NCCIH. Asian Ginseng: Usefulness and Safety (Last Updated: 2025-02), 2025-02. nccih.nih.gov
- NIH LiverTox (NIDDK). Ginseng (Last Update: March 14, 2018), 2018-03-14. ncbi.nlm.nih.gov
- European Medicines Agency, HMPC. European Union herbal monograph on Panax ginseng C.A. Mey., radix, Revision 1 (EMA/HMPC/27744/2023; adopted 29 May 2024), 2024-05-29. ema.europa.eu
- Health Canada, NNHPD. Monograph: Panax ginseng (dated June 27, 2025), 2025-06-27. webprod.hc-sc.gc.ca
- National Toxicology Program. TR-567: Toxicology and Carcinogenesis Studies of Ginseng (CASRN 50647-08-0) in F344/N Rats and B6C3F1 Mice (Gavage Studies) (2011), 2011. ntp.niehs.nih.gov
- IARC Monographs. List of Classifications (retrieved October 29, 2026), 2026-10-29. monographs.iarc.who.int
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of October 23, 2026), 2026-10-23. ecfr.gov
- GBIF species API: IUCN Red List category for Panax ginseng C.A.Mey. (usageKey 5372262), 2026-10-29. api.gbif.org
- CITES/UNEP-WCMC Species+. Panax ginseng, taxon concept 19207 (retrieved October 29, 2026), 2026-10-29. speciesplus.net
- Külkamp J, Osman AG, Katragunta K, Avula B, Khan IA, Chittiboyina AG. Microscopy combined with LC-UV analysis as a tool for authentication of ginseng species used in traditional medicine and detection of their adulterants. J Diet Suppl 2026;23(4):475-489 (PMID 42262747), 2026-06-09. pubmed.ncbi.nlm.nih.gov
Sources
- NCCIH. Asian Ginseng: Usefulness and Safety (Last Updated: 2025-02), 2025-02. nccih.nih.gov
- NIH LiverTox (NIDDK). Ginseng (Last Update: 2018-03-14), 2018-03-14. ncbi.nlm.nih.gov
- European Medicines Agency, HMPC. Ginseng radix (ginseng) - herbal medicinal product, 2026-03-12. ema.europa.eu
- Park SH, et al. Effects of Panax ginseng on hyperglycemia, hypertension, and hyperlipidemia: a systematic review and meta-analysis. J Ginseng Res 2022;46(2):188-205 (PMID 35509826), 2021-10-13. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.